Dompé Farmaceutici S.p.a
Clinical trials sponsored by Dompé Farmaceutici S.p.a, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drops aim to soothe dry eye sufferers Results expected Jan 2027 (estimated)
- New eye drops aim to stop itching and eye damage from severe allergies Results expected Mar 2027 (estimated)
- Nasal spray could reverse sudden blindness in groundbreaking trial Results expected Sep 2027 (estimated)
-
Eye drop breakthrough: nerve growth factor heals corneal wounds in phase 3 trial
Cure Recruiting nowThis study tests an eye drop containing a human nerve growth factor to help heal persistent corneal defects (wounds on the eye's surface that won't close). About 150 adults with such wounds will receive either the active drop or a placebo. The goal is to see if the drop can fully…
Phase 3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Cure
Last updated Jul 18, 2026 00:00 UTC
-
Nasal spray could reverse sudden blindness in groundbreaking trial
Disease control Recruiting nowThis study tests a nasal spray called cenegermin to see if it can improve vision in people who recently lost eyesight from a condition called NAION (a stroke in the optic nerve). About 272 adults will receive either the spray or a placebo. The goal is to measure if more people ga…
Phase 3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New eye drops aim to soothe dry eye sufferers
Symptom relief Recruiting nowThis study tests a new eye drop called DFL24498 in people with dry eye disease. About 417 adults will use the drops four times a day for 12 weeks. Researchers will check if the drops improve eye surface health and reduce dryness symptoms compared to a placebo.
Phase 2 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
New eye drops aim to stop itching and eye damage from severe allergies
Symptom relief Recruiting nowThis Phase 3 trial tests DFL24498 eye drops in 138 adults with atopic keratoconjunctivitis (AKC), a severe allergic eye condition. The drops are given twice daily for 12 weeks to see if they reduce eye itching and corneal damage compared to a placebo. Participants must have AKC i…
Phase 3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC